A physician checks the chart. Patient is 52. CDC guidelines recommend pneumococcal vaccination. She brings it up, cites the guidelines, explains the one-time dosing. The patient nods along.
Then says: "Maybe next month."
The physician makes a note and moves on. The conversation that just determined whether that patient gets vaccinated is gone — unheard, unanalyzed, invisible to the pharma team that spent years building the clinical case behind it.
This is the gap at the center of vaccine commercialization. And new data from ZoomRx puts hard numbers on exactly how wide it is.
NRx data tells you what gets prescribed. Message recall surveys tell you what physicians remember from a rep visit. ATU studies tell you where a product sits in the treatment hierarchy.
None of them tell you what happens in the exam room when a patient pushes back.
ZoomRx's HCP-Patient Conversations methodology fills that gap — recording real clinical interactions with full patient and physician consent, across 800+ unique HCPs, 20 MD specialties, and 100+ indications. The result is the first large-scale view into how vaccine decisions are actually made — not reported, not recalled. Made.
Most pharmaceutical decisions are physician-led. A prescription is written; the patient fills it. Vaccines require something harder: active patient consent, in the room, that day, often without the urgency of an acute illness.
Post-COVID, this dynamic has intensified. The hesitancy showing up in exam rooms today isn't philosophical opposition. It's quieter, more common, and — crucially — more addressable. But only if the physician knows what to do with it in real time.
The ZoomRx data reveals that hesitancy is present in nearly every vaccine conversation. And in the vast majority of cases, it isn't refusal. It's a request for reassurance.
What happens in the next 60 seconds determines the outcome.
Across thousands of analyzed conversations, ZoomRx identified a consistent three-act structure in physician interactions that led to same-visit vaccine acceptance — and a clear breakdown pattern in those that ended in deferral.
The opening move matters more than most physicians realize. The physicians who achieved acceptance didn't lead with efficacy data or mechanism of action. They led with a frame — a reason for the patient to pay attention before any recommendation was made. Three distinct framing approaches appear consistently in the data. Each works differently depending on the patient.
The hesitancy moment — Act 2 — is where most training programs fall short. The data identifies distinct hesitancy types in this dataset, each requiring a different response. Treating them as a single category is one of the most common and costly mistakes in HCP support design.
And Act 3 contains the dataset's most counterintuitive finding — a specific type of physician response that appears most consistently in the moments immediately before acceptance, yet is almost entirely absent from current pharma training materials.
Same-visit acceptance rates in this dataset range from 3 in 4 patients to 9 in 10 — depending on the vaccine type and how the conversation was handled.
The gap between those numbers isn't clinical. It's conversational.
Deferral — the "maybe next month" response — is consistently driven by one missing element in the physician's message. Patients who deferred had, in most cases, received all the clinical information they needed. What they didn't receive was a reason to act today. That reason is designable. It can be built into HCP training and field messaging. Most vaccine brands haven't built it in yet.
The full ZoomRx whitepaper goes beyond the framework. It breaks down exact language patterns tied to acceptance versus deferral, quantifies hesitancy types by frequency and recoverability, and translates the conversation data into four concrete actions for pharma teams designing HCP support tools.
If you build vaccine training programs, design field messaging, or develop medical affairs materials — this data will change how you think about all three.